Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Hyperkeratosis? 411 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 411 reports of Hyperkeratosis have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 1.1% of all adverse event reports for CABOZANTINIB S-MALATE.

411
Reports of Hyperkeratosis with CABOZANTINIB S-MALATE
1.1%
of all CABOZANTINIB S-MALATE reports
11
Deaths
31
Hospitalizations

How Dangerous Is Hyperkeratosis From CABOZANTINIB S-MALATE?

Of the 411 reports, 11 (2.7%) resulted in death, 31 (7.5%) required hospitalization.

Is Hyperkeratosis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 411 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Hyperkeratosis?

ADALIMUMAB (332) SUNITINIB MALATE (170) ETANERCEPT (168) SORAFENIB (150) METHOTREXATE (149) VEMURAFENIB (145) REGORAFENIB (136) RIPRETINIB (124) RITUXIMAB (121) TOCILIZUMAB (103)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Hyperkeratosis Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Hyperkeratosis Reports All Drugs Causing Hyperkeratosis CABOZANTINIB S-MALATE Demographics